Pals D T, Lawson J A, Couch S J
Upjohn Company, Cardiovascular Diseases Research, Kalamazoo, MI 49001.
J Pharmacol Methods. 1990 Jul;23(4):239-45. doi: 10.1016/0160-5402(90)90052-m.
A rat model that provides a rapid method for the in vivo evaluation of potential inhibitors of human renin has been developed and validated. Recombinant human renin was infused intravenously into anesthetized, nephrectomized, ganglion-blocked rats. The resulting blood pressure had an approximate 60 mm Hg human renin-dependent component. The angiotensin I to angiotensin II converting enzyme inhibitor, captopril, and the renin inhibitor, ditekiren (U-71038), were capable of abolishing this component after oral administration. Oral administration of ditekiren to rats receiving human renin infusions evoked dose-dependent hypotensive responses that were greater in magnitude and longer in duration than those elicited in rats receiving hog renin infusions. Observations made in the renin-infused rats reflected the results of in vitro kinetic studies that had indicated a greater binding affinity of ditekiren for human renin than for hog renin.
一种能够为体内评估人肾素潜在抑制剂提供快速方法的大鼠模型已被开发并验证。将重组人肾素静脉注射到麻醉、肾切除、神经节阻断的大鼠体内。由此产生的血压有一个约60毫米汞柱的人肾素依赖性成分。血管紧张素I转化为血管紧张素II的转化酶抑制剂卡托普利和肾素抑制剂替吉仑(U-71038)在口服给药后能够消除该成分。给接受人肾素输注的大鼠口服替吉仑会引起剂量依赖性的降压反应,其幅度更大、持续时间更长,比接受猪肾素输注的大鼠所引发的反应更明显。在接受肾素输注的大鼠中所观察到的结果反映了体外动力学研究的结果,该研究表明替吉仑与人肾素的结合亲和力大于与猪肾素的结合亲和力。